BACE1 and Alzheimer disease: Studies have shown that BACE-1 is elevated in the AD brains (Singh et al., 2022; Zhao et al., 2007) This increased activity leads to higher production of Aβ peptides, particularly Aβ42, which have a greater propensity to aggregate and form plaques (Sadleir et al., 2016) The overproduction and deposition of Aβ peptides contribute to neurotoxicity and the progression of AD pathology.